Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Aug
10
Today In Oncology
Kinase Inhibitor Approved for Nonsquamous NSCLC With HER2 TKD–Activating Mutations
Potential New Second-Line Standard of Care Emerges in Small Cell Lung Cancer
Mortality in Advanced-Stage Ovarian Cancer—Effect of Neoadjuvant Chemotherapy and Cytoreductive Surgery Case Volume
Smoking Cessation in Cancer Care: Challenges and Opportunities
GLP-1 Receptor Agonists vs Other Glucose-Lowering Drugs: Survival in Older Patients With Cancer and Diabetes
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo